Search clinical trials for: Vimpat

Total 73 results

Universidad Peruana Cayetano Heredia
National Institute of Allergy and Infectious Diseases (NIAID)

Not yet recruiting

One and Two Doses of Oxfendazole Versus a Schedule of Two Doses of Triclabendazole in Chronic Fascioliasis

Fascioliasis
Indiana University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Recruiting

STTEPP: Safety, Tolerability and Dose Limiting Toxicity of Lacosamide in Patients With Painful Chronic Pancreatitis (STTEPP)

Chronic Pain | Opioid-Related Disorders | Opioid Use Disorder | Opioid Dependence | Chronic Pancreatitis | Hyperalgesia | Chronic Pain Syndrome | ERCP | Pancreatic Surgery | Chronic Abdominal Pain

United States
UCB Biopharma SRL

Recruiting

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Lacosamide in Neonates With Repeated Electroencephalographic Neonatal Seizures (LENS)

Epilepsy | Electroencephalographic Neonatal Seizures

United States, Australia, Canada
UCB Pharma

Completed

A Trial to Investigate the Safety, Tolerability and Pharmacokinetics of Intravenous SPM 927

Epilepsy
UCB Pharma

Completed

A Multi-Centre, Randomized, Double-Blind, Placebo Controlled Pilot Trial to Assess the Efficacy, Safety, and Tolerability of SPM 927 in Subjects With Postherpetic Neuralgia (PHN).

Postherpetic Neuralgia
The Hospital for Sick Children
St. Justine's Hospital; University of Waterloo

Completed

Drug Concentrations in Breast Milk and Prediction of Blood Levels of the Breastfed Infants

Breast Feeding

Canada
Leiden University Medical Center

Completed

Combined Effect of Pregabalin and Oxycodone, and Lacosamide and Oxycodone, on Breathing (POLO)

Opioid-induced Respiratory Depression

Netherlands
UCB Pharma

Completed

An Open-label follow-on Trial to Assess the Long-term Safety and Efficacy of Oral SPM 927 in Subjects With Diabetic Neuropathy

Painful Diabetic Neuropathy
UCB BIOSCIENCES, Inc.

Completed

Safety and Efficacy of Lacosamide as Additional Therapy in Patients Suffering From Epileptic Tonic-Clonic Seizures (VALUE)

Epilepsy

United States, Australia, Brazil, Bulgaria, China, Czechia, France, Germany, Hungary, Israel, Italy, Japan, Korea, Republic of, Mexico, Poland, Portugal, Romania, Russian Federation, Slovakia, Spain, Taiwan
UCB Biopharma SRL

Active, not recruiting

A Study to Test the Long-term Use of Oral Lacosamide in Pediatric Study Participants Who Completed NCT01964560 (EP0034) or NCT00938912 (SP848) and Received Lacosamide Treatment

Epilepsy

Georgia, Hungary, Moldova, Republic of, Romania, Taiwan, Ukraine
UCB Pharma

Completed

Study Evaluating Long-term Safety and Efficacy of Lacosamide in Subjects With Painful Distal Diabetic Neuropathy.

Painful Diabetic Neuropathy

Russian Federation, Austria, Belgium, Bulgaria, Czechia, Finland, France, Germany, Hungary, Italy, Poland, Romania, Serbia, Spain, United Kingdom
UCB Biopharma S.P.R.L.
Parexel

Completed

A Clinical Study to Investigate the Long-term Use of Lacosamide as Monotherapy in Subjects Who Completed Study SP0994

Epilepsy

Bulgaria, Finland, France, Germany, Japan, Korea, Republic of, Latvia, Mexico, Philippines, Poland, Romania, Russian Federation, Sweden, Switzerland, Ukraine
Duke University

Terminated

Seizure Prophylaxis in Patients With Glioma or Brain Metastasis

Glioma | Brain Tumor | Glioma of Brain

United States
UCB BIOSCIENCES, Inc.

Completed

Study to Investigate Safety and Tolerability of Intravenous Lacosamide in Children. (ASPIRE)

Epilepsy

United States, Hungary, Italy, Poland, Ukraine
Pakistan Institute of Medical Sciences
Riphah International University

Completed

COMPARISON OF EFFICACY OF DIFFERENT DRUG COMBINATIONS IN ACUTE SCIATICA (EDCLAS)

Sciatica | Sciatica Acute

Pakistan
UCB BIOSCIENCES, Inc.
UCB Biopharma SRL

Completed

A Clinical Study to Investigate the Efficacy and Safety of Lacosamide as an Add on Therapy in Children With Epilepsy With Partial-onset Seizures

Epilepsy

United States, Argentina, Australia, Belgium, Brazil, Bulgaria, China, Colombia, Croatia, Czechia, Estonia, France, Georgia, Greece, Hungary, Israel, Italy, Korea, Republic of, Latvia, Lithuania, Mexico, Moldova, Republic of, Monten... and more
UCB BIOSCIENCES, Inc.

Completed

An Open-Label Study to Determine Safety , Tolerability, and Efficacy of Oral Lacosamide in Children With Epilepsy

Epilepsy

United States, Belgium, China, France, Germany, Hungary, Italy, Japan, Mexico, Poland, Ukraine
UCB Pharma SA
UCB Japan Co. Ltd.

Completed

Study to Evaluate the Safety, Tolerability, and Efficacy of Long-term Adjunctive Therapy With Lacosamide in Adults With Partial-onset Seizures

Epilepsy | Partial-onset Seizures

China, Japan
UCB BIOSCIENCES, Inc.

Completed

Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects ≥1 Month to <4 Years With Partial-onset Seizures

Epilepsy With Partial-onset Seizures

United States, Argentina, Brazil, Bulgaria, China, Croatia, Czechia, France, Georgia, Greece, Hungary, Israel, Italy, Korea, Republic of, Mexico, Moldova, Republic of, Philippines, Poland, Portugal, Romania, Russian Federation, Se... and more
Boston Medical Center
National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Completed

Lacosamide Effects on Alcohol Self Administration and Craving in Heavy Drinkers

Alcohol Use Disorder

United States
UCB BIOSCIENCES GmbH
Eden Sarl

Completed

Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older (SP0993)

Epilepsy | Monotherapy

United States, Australia, Belgium, Bulgaria, Canada, Czechia, Finland, France, Germany, Greece, Hungary, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Mexico, Philippines, Poland, Portugal, Romania, Russian Federation, Slovakia, Spa... and more
UCB BIOSCIENCES, Inc.
Pharmaceutical Research Associates

Completed

A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications (VALOR)

Epilepsy

United States, Australia, Belgium, Brazil, Bulgaria, China, Czechia, France, Germany, Hungary, Israel, Italy, Japan, Korea, Republic of, Mexico, Poland, Portugal, Romania, Russian Federation, Slovakia, Spain, Taiwan
Le Bonheur Children's Hospital

Completed

IV Lacosamide: The Safety of Intravenous Lacosamide

Epilepsy

United States
Le Bonheur Children's Hospital

Completed

The Safety of Intravenous Lacosamide

Epilepsy

United States
UCB Biopharma S.P.R.L.

No longer available

Compassionate Use Program With Lacosamide in Patients With Partial-onset or Generalized Tonic-clonic Seizures

Epilepsies, Partial
UCB Japan Co. Ltd.

Completed

A Trial to Evaluate the Long Term Safety and Tolerability of Lacosamide Taken as Monotherapy in Adults With Partial-onset Seizures

Epilepsy | Partial-onset Seizures

Japan
UCB Pharma

Completed

A Study to Investigate the Safety and Efficacy of Lacosamide Added to the Patients Current Therapy in Patients Aged 1 Month to Less Than 18 Years Old With Epilepsy Syndromes Associated With Generalized Seizures.

Epilepsy

United States, France, Hungary, Mexico, Poland
UCB Pharma

Completed

A Multicenter, Open-Label Study To Investigate The Safety And Pharmacokinetics Of Lacosamide In Children With Partial Seizures

Epilepsy

United States, Belgium, Mexico
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Lacosamide in Preventing Seizures in Participants With Malignant Glioma

Malignant Glioma

United States
UCB BIOSCIENCES, Inc.

Completed

Trial to Demonstrate the Efficacy and Safety of Conversion to Lacosamide Monotherapy for Partial-onset Seizures (ALEX-MT)

Epilepsy

Austria, United States, Australia, Canada, Denmark, France, Germany, Ireland, Italy, Poland, Puerto Rico, Spain, United Kingdom
UCB Pharma

Completed

Assessing Efficacy and Safety of Lacosamide Compared to Placebo in Reducing Signs and Symptoms of Fibromyalgia Syndrome.

Fibromyalgia Syndrome

United States
UCB Pharma

Completed

Trial to Assess Long-term Lacosamide (LCM) Monotherapy Use and Safety of LCM Monotherapy and Adjunctive Therapy for Partial-onset Seizures

Epilepsy

United States, Australia, Canada, Denmark, Germany, Italy, Poland, United Kingdom, Spain
UCB Pharma

Completed

Study to Investigate Lacosamide as Add-on Therapy in Subjects ≥4 Years to <17 Years of Age With Partial Onset Seizures

Epilepsy

United States, Argentina, Australia, Belgium, Bulgaria, Colombia, Croatia, Czechia, Estonia, Georgia, Hungary, Israel, Italy, Korea, Republic of, Latvia, Lithuania, Mexico, Montenegro, Poland, Romania, Russian Federation, Serbia, Sl... and more
UCB Pharma

Completed

eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam (VERVE)

Epilepsy

United States, Australia, Bulgaria, Denmark, France, Germany, Romania, Spain, Sweden
UCB BIOSCIENCES GmbH
Eden Sarl

Completed

Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older

Epilepsy | Monotherapy

United States, Australia, Belgium, Bulgaria, Canada, Czechia, Finland, France, Germany, Greece, Hungary, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Philippines, Poland, Portugal, Romania, Russian Federation, Slovakia, Spain, Swede... and more
UCB BIOSCIENCES, Inc.

Completed

Open-Label Study to Assess Lacosamide Safety as Add-on Therapy for Primary Generalized Tonic-Clonic Seizures in Subjects With Epilepsy

Epilepsy

United States
UCB Pharma

Completed

A Study Designed to Test the Effectiveness and Safety of Treating Patients With Lacosamide for Migraine Prophylaxis (SP906)

Migraine

United States
UCB Pharma

Completed

To Determine Tolerability and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures

Partial Epilepsies

United States, Poland, United Kingdom, Switzerland, Hungary, Germany, Sweden, Lithuania
UCB Pharma

Completed

Trial to Assess Lacosamide as the First add-on Anti-epileptic Drug Treatment in Patients With Partial-onset Seizures

Partial Epilepsies

United States, Austria, Bulgaria, Czechia, Denmark, Finland, France, Greece, Italy, Mexico, Romania, Russian Federation, Spain, Switzerland, Turkey
UCB BIOSCIENCES, Inc.

Completed

Safety of Intravenous Lacosamide Dose Followed by Twice Daily Oral Lacosamide in Subjects With Partial-onset Seizures

Partial Epilepsies | Partial Onset Seizures

United States
UCB BIOSCIENCES, Inc.

Completed

Study to Assess the Long-term Safety of Oral Lacosamide in Subjects With Partial-onset Seizures

Partial Epilepsies | Partial Onset Seizures

United States
UCB BIOSCIENCES, Inc.

Completed

Open-Label Extension Study to Assess the Safety and Seizure Frequency Associated With Lacosamide for Primary Generalized Tonic-Clonic Seizures in Subjects With Epilepsy

Epilepsy

United States
Aatif Husain
UCB Pharma

Completed

Intravenous Lacosamide Compared With Fosphenytoin in the Treatment of Patients With Frequent Nonconvulsive Seizures (TRENdS)

Nonconvulsive Seizures

United States
UCB Pharma

Completed

Trial to Assess Optimized Dosage of Lacosamide as add-on Therapy in Patients With Partial Onset Seizure (SELF)

Partial Epilepsies

France
Academisch Ziekenhuis Maastricht

Completed

Safety and Tolerability of Lacosamide in Patients With Gain-of-function Nav1.7 Mutations Related Small Fiber Neuropathy

Small Fiber Neuropathy

Netherlands
Evan Fertig
UCB Pharma

Completed

Cognitive and Behavioral Effects of Lacosamide

Epilepsy

United States
Mid-Atlantic Epilepsy and Sleep Center, LLC

Withdrawn

Levetiracetam, Lacosamide and Ketamine as Adjunctive Treatment of Refractory Status Epilepticus

Epilepsy | Status Epilepticus

United States
UCB Pharma

Completed

An Open-label Continuation Trial to Assess the Continued Efficacy and Safety of Ascending Doses of Lacosamide in Subjects With Chronic Refractory Neuropathic Pain

Chronic Refractory Neuropathic Pain

Germany
UCB Pharma

Terminated

Trial to Assess Efficacy and Safety of Lacosamide in Subjects With Osteoarthritis of the Knee

Osteoarthritis

Poland, Germany, Romania, Hungary, United Kingdom, Sweden, Czechia
UCB Pharma

Terminated

Hormonal and Lipid Levels in Male Subjects After a Switch From Carbamazepine to Lacosamide (VICTOR)

Epilepsy, Partial

Austria, Germany, Spain

Search clinical trials for: Vimpat

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Angola

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations